Bdenza - 40MG


Bdenza 40mg defines


Bdenza 40mg tablets are containing an active substance known as Enzalutamide, which has anti-tumor activity by exhibiting androgen receptor inhibitory activity.


Bdenza 40mg


Bdenza 40mgtablets are containing an active substance known as Enzalutamide, which has anti-tumor activity by exhibiting androgen receptor inhibitory activity. Bdenza 40mg is a non steroidal anti-androgen drug; by inhibiting the androgen synthesis and expels anti-neoplastic activity against prostate tumor. Bdenza 40mg is an oral tablet form, which is endorsed by FDA. Enzalutamide is related with a reducing rate of serum enzyme increased during treatment, be that as it may, have not been connected to instances of clinically clear liver damage with jaundice.


Dosage management


Generally Bdenza is available in the strength of 40mg; the usual dose of Enzalutamide is 160mg taken as once a day. Four Bdenza 40mg tablets should be taken as such at whole. Bdenza 40mg tablets should be administered with or without food Do not chew, open or crush the capsules.





Bdenza 40mg pharmacokinetic properties


Absorption:
The maximum plasma concentration time of Enzalutamide is reaches within 1 hour The Cmax value of Enzalutamide and its metabolite are 16.6ng/ml & 12.7ng/ml respectively The steady state value is achieved in day 28 of Bdenza therapy.
Distribution:
After single dose, the apparent volume of distribution of Enzalutamide is 110L The human plasma protein bounds to Enzalutamide at 97 to 98% Nearly 95% of N-desmethyl Enzalutamide is bounds to human plasma protein.
Metabolism:
Enzalutamide undergone hepatic metabolism, The two most important cytochrome isoenzymes like CYP2C8 & CYP3A4 are responsible for metabolism of Enzalutamide; whereas CYP2C8 is involved in the formation of active metabolite of Enzalutamide.
Elimination
The elimination of Enzalutamide is occurs by liver metabolism, whereas 71% excreted through urine; 14% in feces. The clearance value of Enzalutamide after a single dose intake is 0.56L/hr. The mean half life period of Enzalutamide is 5.8 days with approximately 2.8 to 10.2 days.

Dose alteration


If patient accomplished with toxicities with the grade of III, postpone the therapy using with Bdenza 40mg capsules until changed to grade II. Then continue with the same dose or dose will be reduced to 120mg or 80mg depending upon the condition of the patients.

In combination with strong CYP2C8 inhibitors, dosage altered as


Bdenza 40mg capsules, CYP2C8 inhibitors combination should be avoided if possible. Co administration of Bdenza 40mg capsules with strong CYP2C8 inhibitors, the dose of Bdenza should be decreased to 80mg as a single dose. After discontinuation of strong CYP2C8 inhibitors, the dose of Bdenza 40mg capsules should be used as such before the co administration starts.

Mechanism of action


Androgen is a male hormone; testosterone is a one of the hormone secreted from androgen which is responsible for growth of the tumor cells present in the prostate glands. Bdenza 40 mg tablets are comprises of Enzalutamide which acts by inhibiting the binding of androgen into androgen receptor site. This inhibition leads to interfere with signal transduction of receptors and causes growth retardation. The active metabolite of Enzalutamide is N-desmethyl Enzalutamide which is similar to parent form. Bdenza exhibits anti-neoplastic effect by reducing the cell proliferation leads to cell death and reduce the tumor cell volume.

Drug interaction occurs during therapy with Bdenza 40mg


A Bdenza 40mg capsule combines with strong CYP2C8 inducers or inhibitors; Co administration of Bdenza with strong CYP2C8 inhibitors causes elevation of Cmax and AUC (plasma concentration) of Enzalutamide, to avoid this problem during this concomitant reduce the dose of Bdenza to 80mg as a single dose. Co administration of Bdenza with CYP2C8 inducers causes variation in plasma exposure of Bdenza. Avoid this combination if required. Concurrent use of Bdenza tablet with CYP3A4 inhibitors, causes elevating the AUC of Enzalutamide. Concurrent use of Bdenza with strong CYP3A4 inducers causes decreasing the plasmaexposure of Bdenza. Avoid concurrent use of Bdenza with anti-convulsants, anti-mycobacterials, anti-virals, herbal product like st. Johns wort. Enzalutamide is considered as strong CYP3A4 inducer & moderate CYP2C9 & CYP2C19 inducers. Bdenza diminish the plasma exposure to Midazolam, Omeprazole, and warfarin. Concurrent use of Bdenza with drugs metabolized by CYP3A4 like cyclosporine, ergotamine, fentanyl, quinidine, sirolimus or Tacrolimus may leads to reduce their exposure. Avoid concomitant use of warfarin with Bdenza capsules.

Bdenza 40mg safety measures


The major adverse caused during the Bdenza capsules therapy is seizures. Due to avoid the severe problem , the Patient must be counsel with the risk of participating in any action where sudden loss of awareness could make genuine damage themselves or others

Storage


Bdenza capsules should be stored at 200C to 250 F Protect from light, heat & moisture

Pregnancy


The pregnancy category of Enzalutamide X, which means it, may cause fetal harm even to death. Bdenza 40mg should not be recommended in pregnancy conditions.

Pediatric


The potency and effectiveness of Bdenza 40mg capsules should not be evaluated in pediatric patients. In renal & hepatic damaged patients, the dosage adjustment of Bdenza capsules should not be suggested.

Side Effects


Peripheral edema, Back pain, Arthralgia, Musculoskeletal pain, Musculoskeletal stiffness, weakness, Diarrhea, Hot flush, Hypertension, Head ache, Dizziness, Mental impairment, Hypoesthesia, Respiratory tract infection, Insomnia, Anxiety, Hematuria, Pollakiuria, Fall associated injuries, Non pathogenic fractures, Pruritus, Dry skin, Epistaxis, Elevation of AST & ALT, Elevation of bilirubin, Sepsis, Hallucination.



Over dosage


In over dosage condition, seizure may expose largely in the patients who are suspected with over dose of Bdenza.


Contraindication


Bdenza is contraindicated in pregnancy condition, it may cause fetal damge.


Connect With Us

Prescription Medication Policy


1. Anti-Cancer-Drugs.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. Anti-Cancer-Drugs.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the Anti-Cancer-Drugs.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. Anti-Cancer-Drugs.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Anti-Cancer-Drugs.com
6. At Anti-Cancer-Drugs.com, a Caregiver can order prescription medicines on your behalf.